CYP cynata therapeutics limited

Ann: Publication comparing Cymerus MSCs to other MSCs, page-5

  1. 1,036 Posts.
    lightbulb Created with Sketch. 405
    The flaw in your logic is that it makes more sense to sit on GvHD until the Phase 2 results read-out. Why? Because between now and then, success is not a certainty. Retail investors, let alone big pharma, know and understand this.

    The consequence of a deal now would be a significantly lower upfront payment, probably contingent on the results, anyway. It is likely that milestone and/or royalties would also be lower. So why not wait, and if the results are good, negotiate from a position of power?

    Cynata's development has been a very slow burn, nearly 11 years since listing. I'm prepared to wait another 12-18 months if it means a GvHD deal will be more financially successful.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
17.5¢
Change
-0.005(2.78%)
Mkt cap ! $39.54M
Open High Low Value Volume
17.5¢ 17.5¢ 17.5¢ $6.287K 35.92K

Buyers (Bids)

No. Vol. Price($)
2 67866 17.0¢
 

Sellers (Offers)

Price($) Vol. No.
18.0¢ 27766 2
View Market Depth
Last trade - 11.42am 29/07/2025 (20 minute delay) ?
CYP (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.